Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...
Dupilumab decreases general and type 2 inflammatory biomarker levels in children with moderate to severe atopic dermatitis.
On Thursday, the FDA approved Elanco Animal Health Incorporated’s (NYSE:ELAN) Zenrelia, a once-daily oral JAK inhibitor for ...
UNION therapeutics A/S (UNION), a privately held, clinical stage, pharmaceutical development company focused on immunology, today announced ADESOS Phase 2b results selected as a late-breaking oral ...
Introduction: Eczema, also known as atopic dermatitis, is a common skin condition characterized by dry, itchy skin. While ...
15h
Elanco Animal Health Inc. (ELAN) announced the U.S. Food and Drug Administration has approved Zenrelia, a convenient once-daily oral ...
Pharmaceutical firms are urged to capitalise on current trends in AD trials. The atopic dermatitis (AD) market is projected ...
Basel, Switzerland Friday, September 20, 2024, 13:00 Hrs [IST] ...
The FDA announced earlier today that ilunocitinib tablets (Zenrelia; Elanco) has received its approval. The latest drug from ...
U.S. Food and Drug Administration approves Zenrelia, a once-daily oral JAK inhibitor for dogs with allergic and atopic ...
The oral drug, Zenrelia, is to control pruritus, or itching, associated with allergic dermatitis and control of atopic ...
BD expands capacity for advanced prefillable syringes and enhances injection experience for next generation of biologics: Le ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback